Healios
Healios is dedicated to expanding the options for patients to 'live' through regenerative medicine, aiming to deliver new treatments and hope to patients worldwide. The company focuses on research, development, and manufacturing of cell therapy and regenerative medicine products, with a mission to foster a 'Life Explosion' that enriches lives globally. Additionally, Healios is advancing the use of Universal Donor Cells (UDC) for next-generation cancer immunotherapy, ophthalmology, and organ progenitors, promoting in-house development of regenerative medicines and collaborations with research institutions to develop new treatments.
Industries
Nr. of Employees
medium (51-250)
Products
Allogeneic multipotent somatic stem cell therapeutic (systemic IV)
A cryopreserved allogeneic multipotent stem cell product developed for intravenous administration to modulate acute inflammation and support tissue protection/repair in indications such as ischemic stroke, ARDS and trauma.
iPSC-derived retinal pigment epithelium (RPE) cell therapy
A cell-replacement therapy consisting of iPSC-derived RPE cells or RPE cell sheets intended to restore or maintain retinal function in RPE-defect and age-related macular degeneration indications.
iPSC-derived gene-edited NK cell immunotherapy
An engineered iPSC-derived NK cell product with gene edits to enhance anti-cancer activity, intended for immuno-oncology applications against solid tumors.
Vascularized liver organ primordia (3D organ constructs)
Three-dimensional, vascularized organ primordia produced from precursor cells designed for transplantation to restore or augment liver function in preclinical models of liver failure and metabolic disease.
Allogeneic multipotent somatic stem cell therapeutic (systemic IV)
A cryopreserved allogeneic multipotent stem cell product developed for intravenous administration to modulate acute inflammation and support tissue protection/repair in indications such as ischemic stroke, ARDS and trauma.
iPSC-derived retinal pigment epithelium (RPE) cell therapy
A cell-replacement therapy consisting of iPSC-derived RPE cells or RPE cell sheets intended to restore or maintain retinal function in RPE-defect and age-related macular degeneration indications.
iPSC-derived gene-edited NK cell immunotherapy
An engineered iPSC-derived NK cell product with gene edits to enhance anti-cancer activity, intended for immuno-oncology applications against solid tumors.
Vascularized liver organ primordia (3D organ constructs)
Three-dimensional, vascularized organ primordia produced from precursor cells designed for transplantation to restore or augment liver function in preclinical models of liver failure and metabolic disease.
Services
CDMO services for cell therapy manufacturing
Contract development and GMP manufacturing support for cell therapy products provided via a dedicated subsidiary model.
Clinical development services for cell therapies
Design, registration and conduct of randomized multicenter clinical trials (Phase II/III), including data management and analysis support for cell therapy products.
Research collaboration and licensing support
Formation and management of academic and industry partnerships, licensing transactions and joint ventures to advance translational programs and access external IP.
Venture fund and investment management for regenerative medicine
Operation of fund and fund-management entities to support investments and ecosystem development for regenerative medicine startups and technologies.
CDMO services for cell therapy manufacturing
Contract development and GMP manufacturing support for cell therapy products provided via a dedicated subsidiary model.
Clinical development services for cell therapies
Design, registration and conduct of randomized multicenter clinical trials (Phase II/III), including data management and analysis support for cell therapy products.
Research collaboration and licensing support
Formation and management of academic and industry partnerships, licensing transactions and joint ventures to advance translational programs and access external IP.
Venture fund and investment management for regenerative medicine
Operation of fund and fund-management entities to support investments and ecosystem development for regenerative medicine startups and technologies.
Expertise Areas
- Universal-donor iPSC platform development
- Gene editing for immune modulation and safety
- iPSC-derived immune effector cell engineering
- Somatic (multipotent) stem cell therapeutics
Key Technologies
- Induced pluripotent stem cell (iPSC) platforms
- Gene editing of cellular genomes
- Immune-evasive universal-donor iPSC lines
- iPSC-derived natural killer (NK) cell engineering